REFERENCES
- Chow, S. C., Shao, J., Wang, H. (2003). Sample Size Calculations in Clinical Research. Boca Raton, FL: CRC Press.
- Chow, S. C., Liu, J. P. (2010a). Statistical assessment of biosimilar products. Journal of Biopharmaceutical Statistics 20:10–30.
- Chow, S. C., Hsieh, T. C., Chi, E., Yang J. (2010b). A comparison of moment-based and probability-based criteria for assessment of follow-on biologics. Journal of Biopharmaceutical Statistics 20:31–45.
- Chow, S. C., Lu, Q., Tse, S. K., Chi, E. (2010c). Statistical methods for assessment of biosimilarity using biomarker data. Journal of Biopharmaceutical Statistics 20:90–105.
- Chow, S. C., Endrenyi, L., Lachenbruch, P. A., Yang, L. Y., Chi, E. (2011). Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars 1: 13–26.
- European Medicines Agency. (2006). Assessment report for Omitrope. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf.
- European Medicines Agency. (2007a). Assessment report for Abseamed. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000727/WC500020660.pdf.
- European Medicines Agency. (2007b). Assessment report for Retacrit. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000872/WC500116652.pdf.
- European Medicines Agency. (2008). Assessment report for Filgrastim Ratiopharm. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000824/WC500022727.pdf.
- Hsieh, T. C., Chow, S. C., Liu, J. P., Hsiao, C. F., Chi, E. (2010). Statistical test for evaluation of biosimilarity in variability of follow-on biologics. Journal of Biopharmaceutical Statistics 20:75–89.
- Lei, L., Olson, K. (2010). Evaluating statistical methods to establish clinical similarity of two biologics. Journal of Biopharmaceutical Statistics 20:62–74.
- U.S. Food and Drug Administration. (2012). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
- World Health Organization. (2009). Guidelines on Evaluation of Similar Biotherapeutic Products. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
- Zhang N., Yang, J., Chow, S. C., Endrenyi, L., and Chi, E. (2013). Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics. Statistics in Medicine 32(3):424–433.